Quick Answer
UroGen Pharma Ltd. reported Total Revenue of $109.79 million for fiscal year 2025.
UroGen Pharma Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $109.79M +21.4% |
$90.40M +9.3% |
$82.71M +28.5% |
$64.36M +34.0% |
$48.04M +307.2% |
$11.80M +65450.0% |
| Revenue (ASC 606) | $109.79M +21.4% |
$90.40M +9.3% |
$82.71M +28.5% |
$64.36M +34.0% |
$48.04M +307.2% |
$11.80M +65450.0% |
| Net Income | -$153.49M -21.0% |
-$126.87M -24.1% |
-$102.24M +6.9% |
-$109.78M +0.9% |
-$110.82M +13.7% |
-$128.48M -22.2% |
| Total Assets | $200.46M -29.8% |
$285.71M +60.2% |
$178.31M +31.5% |
$135.62M +13.3% |
$119.75M -1.9% |
$122.00M -39.7% |
| Cash and Equivalents | $110.75M -35.6% |
$171.99M +81.0% |
$95.00M +71.5% |
$55.41M +24.9% |
$44.36M -16.1% |
$52.86M +6.4% |
| Long-Term Debt | $122.21M +0.4% |
$121.73M +23.5% |
$98.55M +1.0% |
$97.54M | $0.00 | — |
| Stockholders Equity | -$105.47M -1098.2% |
-$8.80M +86.5% |
-$65.21M +27.0% |
-$89.36M -1162.2% |
$8.41M -91.3% |
$96.36M -46.6% |
| R&D Expense | $67.11M +17.4% |
$57.15M +25.3% |
$45.61M -13.8% |
$52.91M +11.0% |
$47.64M +0.7% |
$47.31M -4.0% |
| Operating Income | -$124.86M -29.0% |
-$96.78M -47.7% |
-$65.54M +17.1% |
-$79.04M +14.4% |
-$92.29M +27.2% |
-$126.74M -15.8% |
| Gross Profit | $97.34M +19.4% |
$81.52M +11.1% |
$73.35M +29.4% |
$56.70M +32.2% |
$42.88M +297.5% |
$10.79M +59844.4% |
| Shares Outstanding | 48.35M +14.5% |
42.23M +30.0% |
32.49M +40.5% |
23.13M +3.0% |
22.46M +1.3% |
22.17M +5.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $27.48M | +9.0% | +13.5% |
| Revenue (ASC 606) | September 30, 2025 | $27.48M | +9.0% | +13.5% |
| Net Income | September 30, 2025 | -$33.35M | -40.9% | +33.2% |
| Total Assets | September 30, 2025 | $185.05M | -38.7% | -11.3% |
| Cash and Equivalents | September 30, 2025 | $90.04M | -27.9% | -3.1% |
| Long-Term Debt | September 30, 2025 | $122.11M | +0.3% | -0.3% |
| Stockholders Equity | September 30, 2025 | -$115.41M | -552.3% | -23.6% |
| R&D Expense | September 30, 2025 | $14.01M | +23.4% | -25.9% |
| Operating Income | September 30, 2025 | -$27.39M | -56.1% | +33.9% |
| Gross Profit | September 30, 2025 | $24.20M | +6.4% | +17.1% |
| Shares Outstanding | September 30, 2025 | 46.78M | +10.9% | +1.3% |
- UroGen Pharma Ltd. reported Total Revenue of $109.79 million for fiscal year 2025.
- UroGen Pharma Ltd. showed an increase of +21.4% in Total Revenue compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Revenue (ASC 606) of $109.79 million for fiscal year 2025.
- UroGen Pharma Ltd. showed an increase of +21.4% in Revenue (ASC 606) compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Net Income of -$153.49 million for fiscal year 2025.
- UroGen Pharma Ltd. showed a decrease of -21.0% in Net Income compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Total Assets of $200.46 million for fiscal year 2025.
- UroGen Pharma Ltd. showed a decrease of -29.8% in Total Assets compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Cash and Equivalents of $110.75 million for fiscal year 2025.
- UroGen Pharma Ltd. showed a decrease of -35.6% in Cash and Equivalents compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Long-Term Debt of $122.21 million for fiscal year 2025.
- UroGen Pharma Ltd. showed an increase of +0.4% in Long-Term Debt compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Stockholders Equity of -$105.47 million for fiscal year 2025.
- UroGen Pharma Ltd. showed a decrease of -1098.2% in Stockholders Equity compared to the prior fiscal year.
- UroGen Pharma Ltd. reported R&D Expense of $67.11 million for fiscal year 2025.
- UroGen Pharma Ltd. showed an increase of +17.4% in R&D Expense compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Operating Income of -$124.86 million for fiscal year 2025.
- UroGen Pharma Ltd. showed a decrease of -29.0% in Operating Income compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Gross Profit of $97.34 million for fiscal year 2025.
- UroGen Pharma Ltd. showed an increase of +19.4% in Gross Profit compared to the prior fiscal year.
- UroGen Pharma Ltd. reported Shares Outstanding of 48.35 million shares for fiscal year 2025.
- UroGen Pharma Ltd. showed an increase of +14.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: